anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open label single sequence single group non-randomized two way drug interaction study in healthy adult volunteers to determine the extent to which quinine, an inducer of cytochrome p450 CYP 3A4, affects the pharmacokinetics of midazolam, an accepted probe drug for CYP 3A4. The study will also determine the extent to which midazolam affects the pharmacokinetics of quinine. This will compare the pharmacokinetics of midazolam and quinine at baseline to their kinetics when they are taken together in 24 normal healthy adult volunteers who will serve as their own controls. All patients will be confined to the study site throughout the entire 11 day study period. On day 1 after a fast of at least 10 hours, all study participants will receive a single oral dose of midazolam 2 mg. Blood will be drawn at times sufficient to adequately define the baseline concentration time curve for midazolam and its metabolite, 1-hydroxy-midazolam. On the morning of day 4, after a 3 day washout period and following a fast of at least 10 hours, all volunteers will begin a regimen of 324 mg of quinine sulfate by mouth every 8 hours. All subjects will continue this regimen from day 4-10 (21 total doses). Blood will be drawn after the first daily dose of quinine on days 4 and 9 at times sufficient to adequately define the baseline and steady state concentration time curves for quinine. Additional blood will be drawn prior to the first daily dose of quinine on days 7,8,9,and 10. On day 10 after a fast of at least a 10 hours, all participants will receive both midazolam 2 mg and quinine 324 mg together. Blood will be drawn a times sufficient to characterize the pharmacokinetics of midazolam, 1-hydroxy-midazolam and quinine under the stated conditions.
Ketamine is commonly used for procedural sedation anaesthesia in paediatric patients undergoing painful procedures in the ED. Ketamine's safety profile is excellent, but ketamine-associated vomiting (KAV) is common. Routine ondansetron prophylaxis could reduce KAV incidence. This literature review evaluated the efficacy of prophylactic ondansetron in reducing KAV incidence. A systematic literature review was performed on databases and trial registries on 14 January 2023 to identify randomised controlled trials. The primary outcome was reduction in KAV incidence, for any route of prophylactic ondansetron, in ED and up to 24 h post-discharge. ED length of stay, parental satisfaction and time to resumption of normal diet were secondary outcomes. Data analysis was performed using Revman 5.3. Meta-analysis was performed using random effects modelling. Risk of bias was assessed using the Cochrane Risk-of-Bias 2 tool. Evidence quality was assessed using Grading of Recommendation, Assessment Development and Evaluation methodology. Five trials with 920 participants met the eligibility criteria. Prophylactic ondansetron resulted in a reduction in KAV incidence overall odds ratio of 0.51 (95% confidence interval: 0.36-0.73). Intravenous and intramuscular prophylactic ondansetron showed benefit whereas the effect of oral administration was unclear. There was no difference between groups for secondary outcomes overall. The quality of evidence was deemed to be low overall because of high risk of bias and imprecision in outcome measures. This review found low to moderate certainty evidence that prophylactic ondansetron reduces KAV incidence. Methodologically rigorous research, with appropriately timed prophylactic ondansetron based on the route of administration, would further elucidate prophylactic oral ondansetron's efficacy.
The invention discloses a golden ointment nanometer preparation. The golden ointment nanometer preparation is prepared by taking golden lotion or golden ointment as a raw material and taking a dopamine microsphere as a carrier. A preparation method of the golden ointment nanometer preparation comprises the following steps: firstly extracting active ingredients of the golden lotion or the golden ointment, and then absorbing the active ingredients on the dopamine microsphere carrier. As the nanometer material is relatively small in radius and large in specific surface area, the penetrability of the golden ointment nanometer preparation for the tissue is also increased relatively, and due to the adhesion property thereof, the standing time of the medicine on the absorption site is prolonged, the medicine can be released, the blood concentration is increased, the acting time of the medicine is prolonged, further, the medicine degrading is reduced, the medicine stability is improved, and the bioavailability of a nanometer medicine-carrying system is also improved. Therefore, the golden ointment nanometer preparation has good curative effects for traumatic injuries, has the efficacy of promoting blood circulation to remove blood stasis, and the like. The inventor further establishes the corresponding preparation method of the golden ointment nanometer preparation. The method has the advantages of easily available raw materials, low cost, simplicity in operation and no pollution.
<P>PROBLEM TO BE SOLVED: To provide a tea for health the water extract of which is easy to drink and tasty and effectively acts for prevention and suppression of allergic reaction that induces allergic rhinitis such as pollenosis, etc., prevention and suppression of lipid metabolism abnormality such as diabetic mellitus, hyperlipidemia, etc., prevention of obesity and diet, and is free from a rapid expression of efficacy together with toxicity and an adverse reaction.  <P>SOLUTION: The tea for health comprises 40 pts.wt. (dried weight) of Rubus suavissimus S. Lee belonging to Rosacea Rubus (stem:leaf=1:1) dried by roasting, 30 pts.wt. (dried weight) of above-ground portions of Smallanthus sonchifolia (stem:leaf=1:1) obtained by roast drying and 30 pts.wt. (dried weight) of Acanthopanax senticosus Harms (root:stem:leaf=1:1:1) obtained by roast drying, and 3-6 g of the tea is put into 1000 ml of warm water and extracted for 2 to 5 min, and the extract is recommended to drink three times a day and 350 ml for each time.  <P>COPYRIGHT: (C)2003,JPO
OBJECTIVES: The aims are (a) assessment of the prevalence of psychosocial emergencies in the emergency department (ED), (b) determination of the proportion of cases not coded as diagnosis (unreported cases), and (c) characterization of identified patients.
METHODS: In a retrospective study, psychosocial emergencies in one week were identified from routine documentation of the central ED of the Charité - Universitätsmedizin Berlin, Charité Campus Mitte (CCM). After exclusion of planned admitted cases, 862 patients were included in the study. The identified psychosocial emergencies were descriptively analyzed with regard to their sociodemographic and clinical characteristics and compared with other emergencies.
RESULTS: The prevalence of psychosocial emergencies in the reported period was 11.9% (n = 103). A large proportion of psychosocial emergencies were not coded (35.9%) or not fully coded (20.4%) as an ICD diagnosis (unreported cases). There was a statistically relevant difference in gender distribution with a significantly higher proportion of males among psychosocial emergencies (70.9%) compared to other emergencies (50.7%; p < 0.0001). The two most common treatment causes among psychosocial emergencies were substance abuse (66.0%) and homelessness (20.4%).
CONCLUSIONS: This study shows a relevant proportion of psychosocial emergencies among all treatments in ED routine data and a high proportion of cases not captured in the coded diagnoses. EDs thus represent an important point of contact for vulnerable patient groups but standardized screening and identification are still lacking.
Participants received access to the See Me Smoke-Free mobile application (app) delivered via smart phone, and were asked to use the app "most days" for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmaceutical industry, particularly to a stress protector. Administration of Vicia varia herb flavonoid 7-rutinoside diosmetin as a stress protector. Vicia varia herb flavonoid 7-rutinoside diosmetin is effective as a stress protector. ^ EFFECT: agent decreases the area and number of ulcerous defects of a gastric mucosa reliably; decreases the weight of adrenal glands and increases the weight of a thymus; considerably reduces gastric and blood serum lipid peroxidation activity; reduces intensity of a gastric mucosa injury. ^ 3 dwg, 3 tbl, 1 ex
Moldable bone implants for use in a bone defect or wound include a plurality of biocompatible granules and a biocompatible polymer that together form an implant mass. The polymer is softened with a plasticizer to make the implant mass moldable. The plasticizer can dissipate or be extracted to cause the implant mass to harden. The implant mass can be shaped in-situ or ex-situ. Implants formed in-situ are shaped by the bone defect or wound. The implant becomes hard through contact with body fluids, which extracts the plasticizer from the implant mass. Bone implants formed ex-situ, such as in a mold, are shaped by a mold, for example, and then hardened by placing the implant mass in contact with a hardening agent, such as water, which extracts the plasticizer from the implant mass. The shaped, hardened implant can be placed into a bone defect of corresponding size and shape.
Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
The safety, pharmacokinetics, and efficacy of ledipasvir and sofosbuvir for treatment of HCV genotype 1 and 4 infection in treatment-naïve and treatment-experienced pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis have been established in an open-label, multicenter clinical trial (Study 1116, N=226; 186 treatment-naïve, 40 treatment-experienced) and are comparable to that observed in adults.

The safety and efficacy of ledipasvir and sofosbuvir for treatment of HCV genotypes 5 or 6 infection in pediatric patients 3 years of age and older are supported by comparable ledipasvir, sofosbuvir, and GS-331007 exposures between adults and pediatric patients [see Dosage and Administration (2.2 and 2.4), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.3, 14.6, 14.7)]. Similar rationale is used to support dosing recommendations for pediatric patients with HCV genotype 1 infection who have decompensated cirrhosis (Child-Pugh B or C) and for pediatric patients with HCV genotype 1 and 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.

In patients with severe renal impairment, including those requiring dialysis, exposures of GS-331007, the inactive metabolite of sofosbuvir, are increased [see Clinical Pharmacology (12.3)]. No data are available regarding the safety of ledipasvir and sofosbuvir in pediatric patients with renal impairment [see Use in Specific Populations (8.6)].

The safety and efficacy of ledipasvir and sofosbuvir have not been established in pediatric patients less than 3 years of age.
<P>PROBLEM TO BE SOLVED: To provide an oily hair-coloring agent in which a specific amount of organic polymer powder is formulated with a pigment.  <P>SOLUTION: The oily hair-coloring agent is obtained by formulating an oily hair-coloring agent with a pigment and a specific amount of organic polymer powder. The content of the organic polymer powder is preferably 5-40 wt.%, further preferably 10-25 wt.%. An acrylic or silicon-based powder is preferably used as the type of the organic polymer powder. In the oily hair-coloring agent, degree in change of hardness of the oily hair-coloring agent by change of air temperature is small and as a result, the amount of the oily hair-coloring agent is always uniformly taken out when actually used and the hair coloring agent enables natural finish of the colored hair.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Safety and efficacy of Tri-Sprintec® tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. There was no significant difference between Tri-Sprintec tablets and placebo in mean change in total lumbar spine (L1 to L4) and total hip bone mineral density between baseline and Cycle 13 in 123 adolescent females with anorexia nervosa in a double-blind, placebo-controlled, multicenter, one-year treatment duration clinical trial for the Intent To Treat (ITT) population. Use of this product before menarche is not indicated.

14\. Geriatric Use

This product has not been studied in women over 65 years of age and is not indicated in this population.
The invention relates to a therapy vaccine preparation. The preparation comprises immunogen with immunological activity, oligo-poly deoxynucleotide as main adjuvant comprising at least one non-methylated CpG dinucleotide, one or various kinds of oil-phase medium and buffer as water-phase medium. The adjuvant for reinforcing vaccine immunity effect is artificial oligo-poly deoxynucleotide (for short CpG-ODN) containing CpG dinucleotide. The adjuvant activates the immune system by the receptor TLR9 on immunological cells, thereby reinforcing specific immune response direct towards vaccine immunogen. The preparation is a water-in-oil type emulsion. The animal experimental result shows that: the therapy vaccine preparation continuously stimulates the immune system to generate high-titer antibody with stronger inhibition capacity to the gastrointestinal tract tumor.
Neurofibromatosis type 1 (NF1) is a multisystem neurocutaneous disorder. Scoliosis and dural ectasia are features of the associated mesodermal dysplasia. Lateral thoracic meningoceles can develop in NF1 and progressively enlarge due to cerebrospinal fluid (CSF) pulsations. Large meningoceles can cause compressive symptoms in the thorax. We are reporting a case of a NF1 presenting with acute onset respiratory distress, who also had chronic orthostatic headaches. CT chest showed unruptured enlarging bilateral lateral thoracic meningoceles causing lung compression. MRI of the brain and spine showed features of CSF hypotension, explaining the headaches. CSF hypotension with unruptured meningoceles is extremely rare. Management of the condition is challenging since surgical removal is prone to complications due to underlying mesodermal abnormalities. Cystoperitoneal shunting to relieve lung compression may worsen CSF hypotension. A shunt with a programmable valve allowed controlled drainage and successfully relieved lung compression without worsening of orthostatic headaches in our case.
Type 2 diabetes (T2D) is associated with a 3-fold cardiovascular disease (CVD) mortality risk compared with healthy controls, and it is estimated that 30 million adults in the United States have the disease. In recent years the American Diabetes Association (ADA) and American College of Sports Medicine (ACSM) recommend moderate intensity (40-60% heart rate max, HRmax) aerobic exercise 3-5d/wk for the management of T2D. The statement also recognized that higher exercise intensity (\>60% HRmax) predicts better blood glucose control than exercise volume. Cardiovascular health (e.g. fitness, blood pressure, etc.) also appears to respond in an exercise dose dependent manner. Despite these suggestions, many people exercising compensate by eating calories back from exercise, thereby negating weight loss. Moreover, compliance and adherence to exercise and diet medical counsel is disappointingly low.

Recent work has begun to target the best time of day to exercise in effort to improve weight loss and related health. This has evolved in part since circadian biology reveals people tend to become glucose intolerant, and develop insulin resistance and endothelial dysfunction in the evening compared with morning. As a result, it would be reasonable to hypothesize that exercise in the afternoon may be best at combating natural declines in health as well as optimizing training adaptations. However, not all studies agree that afternoon is the best time to exercise. In fact, some have demonstrated that 12 wks of aerobic plus resistance exercise improved glycemic control whether performed in the morning or afternoon in adults with T2D. Moreover, consistent morning exercise has been suggested to improve exercise adherence through possible enjoyment as well as lead to greater weight loss. Taken together, additional work is warranted to understand time of day in which exercise is performed given circadian influence may contribute to variations in favorable metabolic as well as vascular adaptation for CVD prevention/treatment. Excitingly, we have preliminary data showing that afternoon exercise induces greater weight loss, reductions in food intake as well as perceptions of appetite and increased insulin sensitivity when compared to morning exercisers. Thus, the overall purpose of this proposal is to determine whether exercise time of day differentially enhances likelihood of weight loss via appetite regulation as well as glycemic control. Our overarching hypothesis is that afternoon exercise will enhance the effectiveness of exercise to induce weight loss, improve appetite and improve glycemic regulation compared to exercise in the morning. Taken together, findings from this study will inform public health recommendations to contemporary behavioral strategies to treat T2D. The study will also provide much needed experimental evidence to time of day in which exercise is performed influences public health risk.
Unlike other diseases, respiratory diseases are not easy to treat even with modern medicine. For example, for minor circulatory diseases, the affected area may be cut out while looking through an endoscope. Medicine may be administered orally so that the drug directly comes into contact with the affected area to alleviate the condition. Alternatively, the administered medicine may travel through the blood and spread throughout the body, improving the condition around the affected area. However, the respiratory tract is difficult to see through an endoscope, and oral medications are delivered to the respiratory tract through the blood through the digestive system. However, a method of treating respiratory diseases of the present invention is not a method of oral administration or injection of medicinal materials, but the ingredients of the medicinal drug that can treat a patient when breathing go directly into the lungs and sterilize and remove germs or diseased cells, not significantly affecting other organs of the human body, such as the stomach or intestine. There are plants that produce phytoncides that can sterilize and remove cancer cells and harmful bacteria while the ingredients enter the lungs and cause no harm to human bodies. The representative plants are cypress, fir, cedar, pine, and Chamaecyparis pisifera trees, which emit volatile substances with a biocidal effect to the outside through the leaves to exterminate bacteria, fungi, and pests that interfere with their survival. The scent of phytoncide comes from leaves, and these leaves are cut into very small pieces, molded into pills, candies, or jellies to take through the mouth, and chew the same, making the same linger for a long time. Thus, by inhaling the scent into the lungs, a treatment for respiratory diseases of the present invention can sterilize and remove cancer cells, infectious bacteria, and harmful bacteria in the bronchi and lungs.
The present invention relates to a liquid formulation comprising cannabidiol, a stabiliser and a liquid carrier. The liquid carrier includes propylene glycol; and the stabiliser comprises a head portion and a tail portion, wherein the head portion includes one or more reducing moieties and the tail portion comprises a C3-C20 straight or branched aliphatic chain. Preferably the stabiliser is butylated hydroxyanisole (BHA) or 6-O-palmitoyl-L-ascorbic acid (also known as 6-O-AP or ascorbyl palmitate). The formulation may further comprise one or more glyceride compounds from a plant source, nicotine, a flavouring agent and/or a scent agent. Preferably the formulation is substantially free from tetrahydrocannabinol (THC). Also claimed is an e-cigarette liquid comprising the liquid formulation.
We analyzed the symptoms composition of Interstitial Cystitis (IC), the regularity of the evolution of symptoms before and after treatment, and the visualization of the community network, to provide a reference for clinical diagnosis and treatment of Interstitial Cystitis. Based on the outpatient electronic case data of 552 patients with Interstitial Cystitis, we used a complex network community discovery algorithm, directed weighted complex network, and Sankey map to mine the data of the symptoms composition of Interstitial Cystitis, the evolution of symptoms before and after treatment and the visualization of the community network, to analyze the epidemiological characteristics of interstitial cystitis symptoms in the real world. By the community division of the complex network of interstitial cystitis symptoms, We finally obtained three core symptom communities. Among them, symptom community A (bladder-related symptoms) is the symptom community with the highest proportion of nodes (60.00%) in the complex network of Interstitial Cystitis, symptom community B (non-bladder-related symptoms 1) ranks second (32.00%) in a complex network of Interstitial Cystitis, and symptom community C (non-bladder-related symptoms 2) has the lowest proportion (8.00%). There is a complex evolutionary relationship between the symptoms of Interstitial Cystitis before and after treatment. Among the single symptoms before and after treatment, the decreased rate of Day frequency is 93.22%, and the reduced urgency rate is 93.07%. The decline rate of Nocturia was 82.33%. From the perspective of different communities, the overall symptoms of symptom community A decreased by 34.39% after treatment, the general symptoms of symptom community B decreased by 35.37%, and the prevalent symptoms of symptom community C decreased by 71.43%. In the case of using diet regulation treatment to treat bladder pain, the cure rate of bladder pain can reach 22.67%. The cure rate of burning in bladders can get 15.38% with Percutaneous Sacral neuromodulation, 96.95% with diet regulation treatment, and 100% with Percutaneous Sacral neuromodulation. When using behavioral physiotherapy to treat bladder pain, 3.57% of the patient's symptoms change to bladder discomfort; 4% of the patient's symptoms change to bladder discomfort when using oral medicine to treat bladder pain.Symptom research methods based on community findings can effectively explore the rule of symptom outcome of Interstitial Cystitis before and after treatment, and the results are highly interpretable by professionals. The cover image is based on the Original Article Research on symptoms composition, time series evolution, and network visualisation of interstitial cystitis based on complex network community discovery algorithm by Lei Pang et al., https://doi.org/10.1049/syb2.12083.